Vertex Pharmaceuticals Inc. Stock

While some stocks have responded to the 2024 bull market better than others, an abundance of stocks have followed this rising tide. There's no predicting how long this next bull market will last

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known for its expertise in treating cystic fibrosis (CF). The biotech is the market leader, bringing in billions of dollars in revenue and profit

Vertex Pharmaceuticals (NASDAQ: VRTX) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of

As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an

No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects.

Three Motley Fool contributors think they've

Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) continues to grab headlines. Over the past six months, the drugmaker has earned important regulatory approvals and made excellent clinical

Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a

The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered

Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

There are many ways to spend $1,000. One could buy a brand-new flat-screen television, play the lottery, or keep it in a savings account. For people trying to increase their capital, though

Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case.

Three Motley Fool contributors have

It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting

Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could

The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely

My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing

Vertex Pharmaceuticals (NASDAQ: VRTX) has wowed investors in recent times as it's expanded beyond its specialty area of cystic fibrosis (CF) treatment. The company launched Casgevy, a one-time

Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment, and that specialty has helped it generate billions of dollars in earnings. But the company has also

Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial

I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic